Cornerstone Pharmaceuticals (2)

Cornerstone Pharmaceuticals is a private, pre-revenue biotech focused on metabolic oncology, a field targeting the unique energy metabolism of cancer cells. Its core asset is CPI-613 (devimistat), a mitochondrial inhibitor in preclinical combination testing, while it recently divested its glutaminase inhibitor CB-839 (telaglenastat). The company's strategy hinges on demonstrating that disrupting cancer cell metabolism can treat aggressive, recurrent cancers and potentially synergize with existing therapies, though it faces significant clinical and competitive risks inherent to novel oncology pathways.

Small molecule inhibitors targeting altered metabolic pathways in cancer cells, specifically mitochondrial energy production (TCA cycle) and glutamine metabolism.

Cornerstone operates in the niche metabolic oncology space, competing with other biotechs and academic efforts targeting pathways like glycolysis, glutaminolysis, and mitochondrial metabolism. The recent asset sale to Synhale also makes that company a competitor in glutaminase inhibition. Success depends on demonstrating superior efficacy or a unique combination benefit.